<DOC>
	<DOC>NCT00292071</DOC>
	<brief_summary>This is an open-label study of MK0991 in children between 3 to 24 months of age with new onset fever and neutropenia. The purpose of the study is to investigate plasma drug levels of caspofungin.</brief_summary>
	<brief_title>Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Patient is 3 to 24 months of age with one or more of the following conditions: Leukemia, lymphoma, or other cancers Bone marrow or peripheral stem transplantation High dose chemotherapy leading to a decrease in white blood cells Aplastic anemia Patient has an absolute neutrophil count &lt;500 mm3 (a specific type of white blood cell that fights infection) AND at least one recording of fever &gt; 38 degreesC (oral or oral equivalent) within 72 hours of screening. Patient is &lt;3 months or &gt;24 months of age at the time of study drug administration Patient has proven or probable invasive fungal infection at the time of enrollment Patient has certain blood clotting or liver function abnormalities Patient is hemodynamically unstable, exhibits hemodynamic compromise or is not expected to survive at least 5 days Patient is taking rifampin, cyclosporin A, phenytoin, carbamazepine, or phenobarbital.</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>